FDA Commissioner Marty Makary said Sunday the agency supports mRNA vaccines but pharmaceutical companies should bear development costs, not U.S. taxpayers 1.
The stance signals a shift toward industry-funded vaccine research that could impact future drug development timelines and costs for major vaccine makers.
Key Takeaways
- FDA cuts funding for mRNA vaccine development programs
- Commissioner says drugmakers can afford own research costs
- Policy shift may affect future vaccine development timelines
Market reaction & context
The announcement comes amid ongoing regulatory tensions at the FDA, with the agency recently refusing to review Moderna’s mRNA-based flu vaccine 8. Major vaccine manufacturers like Moderna (MRNA) and Pfizer (PFE) have generated billions in revenue from their COVID-19 mRNA vaccines since 2021.
Makary said the Health Department cut funding for mRNA vaccine development because companies that produce these drugs have sufficient resources for independent research 1. The move represents a departure from previous government support for vaccine innovation during public health emergencies.
Regulatory implications
The policy shift reflects broader changes under Makary’s leadership since taking over the FDA. The commissioner has faced criticism over what some describe as a “communications crisis” at the agency regarding vaccine oversight 8.
Industry analysts note that reduced government funding could slow innovation cycles for next-generation vaccines. However, pharmaceutical companies argue they have demonstrated capacity to fund large-scale research programs independently following their COVID-19 vaccine successes.
Industry response
The announcement follows Makary’s recent comments suggesting most medications should be available over-the-counter unless proven unsafe 7. This regulatory philosophy emphasizes market-driven solutions over government intervention in drug development.
“Companies that make the drugs can afford their own research,” Makary said, defending the department’s decision to reduce taxpayer-funded vaccine development 1.
Market outlook
The funding cuts may force vaccine manufacturers to allocate more internal resources toward research and development. This could potentially impact profit margins but may also accelerate private sector innovation as companies seek competitive advantages.
The policy change occurs as the FDA navigates increased scrutiny over its vaccine approval processes and communication strategies. Makary’s approach suggests a more market-oriented regulatory framework going forward.
Not investment advice. For informational purposes only.
References
1(February 23, 2026). “US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost”. Reuters. Retrieved February 23, 2026.
2(February 23, 2026). “US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost”. TradingView News. Retrieved February 23, 2026.
3(February 23, 2026). “US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost”. MarketScreener. Retrieved February 23, 2026.
4(February 23, 2026). “Health & Pharma News | Latest Healthcare Stories”. Reuters. Retrieved February 23, 2026.
5(February 23, 2026). “CDC deputy director abruptly departs agency”. AOL.com. Retrieved February 23, 2026.
6(February 23, 2026). “United States”. US News. Retrieved February 23, 2026.
7(February 18, 2026). “FDA’s Marty Makary: Everything should be over-the-counter unless…”. YouTube/CNBC. Retrieved February 23, 2026.
8(February 20, 2026). “Makary, Prasad Under Fire as FDA Turmoil Reaches President Trump”. BioSpace. Retrieved February 23, 2026.
9(February 23, 2026). “US antitrust enforcers to revamp guidelines on rivals collaborating”. MarketScreener. Retrieved February 23, 2026.